<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7320698\results\search\testTrace\results.xml">
  <result pre="7320698S1473-0502(20)30172-5 doi: 10.1016/j.transci.2020.102867102867 : Article Life-saving effect of convalescent plasma" exact="treatment" post="in covid-19 disease: Clinical trial from eastern Anatolia ErkurtMehmet"/>
  <result pre="(CP) therapy is of interest as no vaccine or specific" exact="treatment" post="is available for emerging viruses such as severe acute"/>
  <result pre="the results of our patients who underwent CP in the" exact="treatment" post="of Covid-19. Methods CP treatment was applied to 26"/>
  <result pre="who underwent CP in the treatment of Covid-19. Methods CP" exact="treatment" post="was applied to 26 Covid-19 patients in intensive care"/>
  <result pre="after complete recovery from patients who had mild or moderate" exact="infection" post="with Sars-Cov-2 infection. The collected CP (200cc) were applied"/>
  <result pre="CP therapy has the potential to provide immediate and promising" exact="treatment" post="options before specific vaccines and treatments are developed. In"/>
  <result pre="stage Covid-19 patients who do not need mechanical ventilation, CP" exact="treatment" post="may be a curative treatment option. Keywords Convalescent plasma"/>
  <result pre="not need mechanical ventilation, CP treatment may be a curative" exact="treatment" post="option. Keywords Convalescent plasma Sars-Cov-2 infection Covid-19 Coronavirus Immun"/>
  <result pre="may be a curative treatment option. Keywords Convalescent plasma Sars-Cov-2" exact="infection" post="Covid-19 Coronavirus Immun plasma 1 Introduction A pneumonia associated"/>
  <result pre="coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1]. The SARS-CoV-2" exact="infection" post="spread rapidly all over the world. As of June"/>
  <result pre="7.553.182 and 423.349 deaths [2]. There are currently no proven" exact="treatment" post="for Coronavirus disease 2019 (Covid-19). There is no effective"/>
  <result pre="2019 (Covid-19). There is no effective antiviral drug in the" exact="treatment" post="of Covid-19 disease. It is an urgent need to"/>
  <result pre="urgent need to seek an alternative strategy, especially in the" exact="treatment" post="of serious patients. Convalescent Plasma (CP) therapy can be"/>
  <result pre="flu epidemic and reduced mortality among plasma recipients [3]. CP" exact="treatment" post="is a reliable treatment option for the prevention and"/>
  <result pre="mortality among plasma recipients [3]. CP treatment is a reliable" exact="treatment" post="option for the prevention and treatment of infectious diseases"/>
  <result pre="treatment is a reliable treatment option for the prevention and" exact="treatment" post="of infectious diseases for more than a hundred years"/>
  <result pre="than a hundred years [4]. However, the benefit of CP" exact="treatment" post="to mortality in Ebola virus disease has not been"/>
  <result pre="[5]. Recently, CP was used as a effective and reliable" exact="treatment" post="option in SARS-CoV-1 and Middle East respiratory syndrome (MERS)"/>
  <result pre="(U.S. FDA) has published guidelines for investigating CP for the" exact="treatment" post="of COVID-19 [8]. CP treatment was used in our"/>
  <result pre="for investigating CP for the treatment of COVID-19 [8]. CP" exact="treatment" post="was used in our center for the first time"/>
  <result pre="the first time in the world after China in the" exact="treatment" post="of Covid-19 disease. The purpose of this study was"/>
  <result pre="Covid-19 patients. 2 Materials and methods 2.1 Study design CP" exact="treatment" post="was applied to 26 Covid-19 patients in intensive care"/>
  <result pre="after complete recovery from patients who had mild or moderate" exact="infection" post="with Sars-Cov-2 infection. 500â€&quot;600 cc plasma was collected from"/>
  <result pre="2.2 Study population PCR positive Covid-19 patients who received CP" exact="treatment" post="were included in the study. Patients with no PCR"/>
  <result pre="prevention of its spread are provided by travel restrictions, patient" exact="isolation" post="and supportive medical care. Some of the treatment options"/>
  <result pre="restrictions, patient isolation and supportive medical care. Some of the" exact="treatment" post="options used in the current treatment of Covid-19 are"/>
  <result pre="care. Some of the treatment options used in the current" exact="treatment" post="of Covid-19 are hydroxychloroquine, lopinavir / ritonavir, azithromycin, favipiravir"/>
  <result pre="some patient populations. CP transfusion has been reported in the" exact="treatment" post="of various infections over the past decades [10]. In"/>
  <result pre="has been used with satisfactory efficacy and safety in the" exact="treatment" post="of SARS-CoV-1, MERS-CoV and 2009 H1N1 outbreak [11,12]. Therefore,"/>
  <result pre="therapy in clinical trials and critical Covid-19 patients without other" exact="treatment" post="options, and has published a guideline for this purpose"/>
  <result pre="a guideline for this purpose [13]. In order for CP" exact="treatment" post="to be effective, it is a prerequisite to find"/>
  <result pre="IgG antibody titer was measured by the Elisa test. CP" exact="treatment" post="was started on the 7th day of admission to"/>
  <result pre="A decrease in viral load has been shown after CP" exact="treatment" post="[14]. Duan et al. added 200â€‰mL of CP containing"/>
  <result pre="containing high neutralizing antibody titers (&amp;gt; 1: 640) to the" exact="treatment" post="of 10 critical patients with Covid-19 (age range 34â€&quot;78)"/>
  <result pre="average of 16.5 days of admission to the hospital. CP" exact="treatment" post="increased the neutralizing antibody titer, oxygen saturation and lymphocyte"/>
  <result pre="and lung lesions in radiological imaging. Compared to the CP" exact="treatment" post="group and the control group (10 patients), there was"/>
  <result pre="while the clinical results of the patient group given CP" exact="treatment" post="were superior (pâ€‰ 11]. Shen et al. has applied"/>
  <result pre="standard therapy was performed to 51 patients. Improvement in CP" exact="treatment" post="group was 51.9 %, improvement in standard treatment group"/>
  <result pre="in CP treatment group was 51.9 %, improvement in standard" exact="treatment" post="group was 43.1 %, and this difference was statistically"/>
  <result pre="Conclusion CP has the potential to provide an urgent promising" exact="treatment" post="option when evaluating existing drugs and developing new specific"/>
  <result pre="stage Covid-19 patients who do not need mechanical ventilation, CP" exact="treatment" post="may be a curative treatment option. Funding This research"/>
  <result pre="not need mechanical ventilation, CP treatment may be a curative" exact="treatment" post="option. Funding This research did not receive any specific"/>
  <result pre="coronavirus disease (COVID-19) dashboard12 June 2020; Available from:2020https://covid19.who.int/?gclid=EAIaIQobChMIz83VtZyC6gIVQuztCh0PrQ3WEAAYASAAEgIFB_D_BwE 3HungI.F.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="Sci1171720209490949632253318 12SooY.Retrospective comparison of convalescent plasma with continuing highâ€�dose methylprednisolone" exact="treatment" post="in SARS patientsClin Microbiol Infect107200467667815214887 13FDAInvestigational COVID-19 convalescent plasma"/>
 </snippets>
</snippetsTree>
